Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immunotherapy for Lung Cancer

Published byΘεοδοσία Βάμβας Modified over 5 years ago

Similar presentations

Presentation on theme: "Immunotherapy for Lung Cancer"— Presentation transcript:

1 Immunotherapy for Lung Cancer
Penelope A. Bradbury, MB BCh, FRACP, Frances A. Shepherd, MD, FRCPC  Journal of Thoracic Oncology  Volume 3, Issue 6, Pages S164-S170 (June 2008) DOI: /JTO.0b013e318174e9a7 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Schematic diagram of cell specific immune system and mechanism of tumor cell evasion. APC indicates antigen-presenting cell; TL, T lymphocyte; CTL, cytotoxic T lymphocyte; MHC, major histocompatibility complex. Foreign antigen is phagocytosed by APCs (e.g., dendritic cells). Antigen is degraded into small peptide sequences that are displayed in combination with MHC II. The APC travels to draining lymph nodes and is in contact with naive T lymphocytes. The APC is activated by interacting with appropriate CD4+ T-helper cells, after which complementary CTLs are activated by the APC by interaction with MHC and costimulatory molecules. Activated CTLs circulate to the periphery searching for specific target. The CTLs induce apoptosis of target cells displaying complementary peptide in combination with MHC class I molecules. Journal of Thoracic Oncology 2008 3, S164-S170DOI: ( /JTO.0b013e318174e9a7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan Meier curves of survival analysis for the l-BLP25 study. A, All patients. B, Patients with locoregional stage 3B disease. BLP indicates BLP25 liposome vaccine. Reproduced with permission from Butts C, Murray N, Maksymiuk A, et al. J Clin Oncol 2005;23:6674–6681. Journal of Thoracic Oncology 2008 3, S164-S170DOI: ( /JTO.0b013e318174e9a7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier curves of survival analysis for the Bec2/BCG Study. A, Overall survival analysis. B, Survival of patients with and without humoral response. Reproduced with permission from Giaccone G, Debruyne C, Felip E, et al. J Clin Oncol 2005;23:6854–6864. Journal of Thoracic Oncology 2008 3, S164-S170DOI: ( /JTO.0b013e318174e9a7) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Immunotherapy for Lung Cancer"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
PUBLISH ONLY Journal of Thoracic Oncology

PUBLISH ONLY Journal of Thoracic Oncology
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape  Hawazin Faruki,

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape  Hawazin Faruki,
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.
Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Similar presentations

Ads by Google